Selective NET inhibition + 5-HT2C agonism + 5-HT2B antagonism. Non-stimulant ADHD treatment approved 2021 (originally marketed in Europe as antidepressant 1970s-2002). No abuse potential.
Half-Life & Elimination Curve (PO: 7h)
Plasma (PO)t½ Decay (7h)
0×t½0h100%(1.46 mg/L)
1×t½7h50%(0.731 mg/L)
2×t½14h25%(0.365 mg/L)
3×t½21h12.5%(0.183 mg/L)
4×t½28h6.3%(91.4 µg/L)
5×t½35h3.1%(45.7 µg/L)
Elimination t½7h (PO)
Rate Constant (ke)0.099 h⁻¹
Time to Peak (Tmax)5h
Est. Peak (Cmax)1.46 mg/L
Clearance (CL)9.7 L/h
97% Washout (5×t½)35h
Dosing Guidelines
Oral (PO): Typical 267 mg (Range: 100–600 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 88% · Volume of Distribution (Vd): 98 L · Absorption (ka): 0.354 h⁻¹ (t½ka ≈ 1.96h) [PMID 34652564]